Market Update (NYSE:MRK): Merck’s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Naïve Adults
March 05, 2014 at 12:16 PM EST
[Business Wire] – Merck , known as MSD outside the United States and Canada, today presented data from the dose-ranging portion of an ongoing Phase 2B clinical trial of doravirine, the company’s investigational . . . → Read More: Market Update (NYSE:MRK): Merck’s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Naïve Adults Similar Articles: Company Update: Johnson & Johnson (NYSE:JNJ) – 9:01 am Johnson & Johnson: Two-year data from INNOVATION trial on INCRAFT AAA stent graft system continues to demonstrate safety and performance in treatment of abdominal aortic Aneurysms Merck & Co. Inc. (NYSE:MRK) – 8:31 am Merck initiates rolling submission of U.S. Biologics License Application for MK-3475, an investigational Anti-PD-1 Immunotherapy, in patients with advanced melanoma; expects to complete application in 1H14 Stock market seasonality mid-year update